News

SHERIDAN, WYOMING – October 15, 2025 – Italian engineering firm SIPA has unveiled the ECS SP130, a next-generation Injection-Stretch-Blow Molding (ISBM) system that marks a major leap forward in packaging production. Designed entirely in Italy, the new machine is built to set a new global benchmark for productivity, quality, and operational versatility in the manufacturing of plastic containers.

Reinventing Performance and Clean Production Standards
The ECS SP130 is engineered to meet the most demanding industrial environments. Capable of handling blow pressures up to 38 bar, it ensures consistent performance even for containers with complex geometries. A “Clean Tech” system eliminates any risk of oil contamination in bottles — a crucial advantage for food and beverage applications where hygiene and purity are non-negotiable.

SHERIDAN, WYOMING – October 15, 2025 – Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron, has achieved another major milestone in its late-stage clinical program. Following its earlier success against Novo Nordisk’s semaglutide, the once-daily oral therapy has now demonstrated superiority over AstraZeneca’s blockbuster Farxiga (dapagliflozin) in two Phase III studies targeting patients with inadequately controlled type 2 diabetes.

Strong Phase III Results Reinforce Competitive Edge
The twin trials, ACHIEVE-2 and ACHIEVE-5, assessed orforglipron’s efficacy and safety in patients whose diabetes remained poorly controlled despite metformin therapy. Both studies met their primary and secondary endpoints, showing significant improvements in key glycemic markers and body weight after 40 weeks of treatment.

SHERIDAN, WYOMING – October 15, 2025 – Sarepta Therapeutics is pressing forward with its limb-girdle muscular dystrophy (LGMD) gene therapy, SRP-9003, despite a strategic pivot earlier this year toward small interfering RNA (siRNA) therapies and ongoing regulatory challenges. New late-stage data presented at the World Muscle Society Congress in Vienna suggest the therapy could still hold clinical and commercial potential—if Sarepta can navigate FDA scrutiny and rebuild trust in its gene therapy platform.

Promising Clinical Outcomes at WMS 2025
At the 30th annual World Muscle Society (WMS) meeting, Sarepta shared Phase III data from its EMERGENE trial evaluating SRP-9003 in 17 LGMD patients. The therapy, designed to restore beta-sarcoglycan expression—a key muscle-stabilizing protein—met its primary endpoint after 60 days of observation.

SHERIDAN, WYOMING – October 15, 2025 – Pelage Pharmaceuticals has raised $120 million in Series B financing to advance its novel stem cell–activating therapy for hair loss into Phase III clinical trials. The funding positions the California-based biotech to accelerate clinical development of PP405, a first-in-class topical molecule designed to rejuvenate dormant hair follicle stem cells and restore natural hair growth.

SHERIDAN, WYOMING – October 15, 2025 – Boehringer Ingelheim is continuing its high-stakes investment strategy in next-generation oncology treatments, signing a deal worth up to $991 million with South Korea’s AimedBio to license an antibody-drug conjugate (ADC) for cancer. The move underscores Boehringer’s accelerating focus on precision oncology and reinforces its growing footprint in the ADC space—one of the most competitive frontiers in cancer therapeutics.

SHERIDAN, WYOMING – October 15, 2025 – Bristol Myers Squibb (BMS) has expanded its artificial intelligence-driven collaboration with insitro, reinforcing its long-term strategy to accelerate therapeutic development in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The renewed deal underscores a shared commitment to leveraging AI and advanced chemistry platforms to unlock new pathways in ALS drug discovery.

AI-Powered Extension Strengthens a Five-Year Alliance

The latest extension adds another year to the 2020 collaboration, with BMS investing up to $20 million to continue joint research using insitro’s advanced ChemML platform. The total deal value could exceed $2 billion through potential discovery, development, and commercial milestones, as well as royalties on any approved therapies.

SHERIDAN, WYOMING – October 15, 2025 – BioCryst Pharmaceuticals is strengthening its hereditary angioedema (HAE) pipeline through the acquisition of Massachusetts-based Astria Therapeutics in a $700 million cash-and-stock deal. The move positions BioCryst to compete more aggressively in the rare disease market by combining its oral HAE treatment, Orladeyo, with Astria’s long-acting injectable candidate, navenibart.

Strategic Expansion into Injectable HAE Therapy
The acquisition gives BioCryst a promising investigational monoclonal antibody, navenibart, currently in Phase III trials for HAE prophylaxis. Designed to inhibit plasma kallikrein — a key driver of HAE attacks — the therapy could offer significant convenience and efficacy improvements over existing injectable options.

SHERIDAN, WYOMING – October 15, 2025 – In a pivotal development for the U.S. biotech sector, Krystal Biotech has received the U.S. Food and Drug Administration’s (FDA) second-ever platform technology designation for its non-replicating HSV-1 viral vector—positioning the company as a key early beneficiary of the agency’s emerging regulatory framework for gene therapy platforms.

Validation of a Versatile Gene Delivery Platform

The FDA’s platform designation recognizes Krystal’s HSV-1 vector technology as a “well-understood and reproducible” delivery system capable of supporting multiple gene therapy programs. Analysts at William Blair described Krystal as “poised to be the first major beneficiary” of this program, highlighting the FDA’s confidence in the HSV-1 vector’s cross-program applicability.

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) and China’s MK Masterwork are deepening their decade-long collaboration to advance automation and robotics in packaging production. The renewed strategic partnership, announced at a joint anniversary event in Tianjin, underscores both companies’ commitment to delivering integrated, end-to-end solutions for the global packaging and printing industry.

A Decade of Partnership Strengthening Global Reach

Since entering a strategic sales agreement in 2015, HEIDELBERG has distributed MK Masterwork’s high-performance finishing systems—including die-cutters, folding carton gluers, and hot-foil stamping machines—outside of China. Over the past decade, approximately 1,500 systems have been installed worldwide, supporting packaging manufacturers in achieving higher efficiency and throughput.

SHERIDAN, WYOMING – October 15, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) brought together more than 200 global industry leaders at its new SHIFT 2025 summit to address one of the printing sector’s most pressing challenges: how to remain competitive amid rising costs, labor shortages, and increasingly fragmented order structures. The event underscored the company’s commitment to driving end-to-end process digitization, automation, and hybrid print production through its evolving Prinect workflow platform and AI-supported solutions like Prinect Touch Free.